India to Yemen Pharmaceutical Export

The pharmaceutical trade between India and Yemen has experienced significant growth over the past decade. In 2019, India's pharmaceutical exports to Yemen were valued at approximately $29.28 million. By 2024, this figure had increased to $80.48 million, indicating a robust expansion in bilateral trade. This upward trajectory reflects India's growing role as a key supplier of pharmaceutical products to Yemen, driven by the increasing demand for quality medicines in the region.

India holds a dominant position in Yemen's pharmaceutical import market. In 2022, India was the leading exporter of "Other medicaments of mixed or unmixed products" to Yemen, with exports valued at $37.24 million. This substantial share underscores India's strategic importance in meeting Yemen's pharmaceutical needs, particularly in providing a diverse range of medications.

Between 2024 and 2026, several key developments have influenced the India-Yemen pharmaceutical trade. In September 2025, Amber Lifesciences initiated pharmaceutical contract manufacturing services in South Yemen, aiming to support healthcare needs in regions with limited local manufacturing capacity. Additionally, in February 2026, the United Nations COMTRADE database updated India's pharmaceutical exports to Yemen, reflecting ongoing trade activities and the dynamic nature of the market.

EXPORT_REGULATORY

Indian pharmaceutical companies seeking to register products in Yemen must adhere to the guidelines set by the Supreme Board of Drugs and Medical Appliances (SBDMA). The registration process requires a comprehensive product dossier, including administrative documents such as a Free Sales Certificate (COPP) legalized by the Yemeni embassy, and pharmaceutical documents detailing the product's composition, manufacturing process, and stability studies. Additionally, a Site Master File is required, and an agent's distribution agreement must be legalized by the Yemeni embassy. Notably, a Good Manufacturing Practice (GMP) inspection is mandatory if the company is not registered in the Gulf Cooperation Council (GCC) countries.

Yemen mandates that pharmaceutical products imported into the country comply with international GMP standards, such as those recognized by the World Health Organization (WHO). Manufacturing facilities must undergo inspections to verify adherence to these standards. The inspection process includes evaluating the facility's quality control, hygiene, and sanitation protocols. Mutual recognition agreements may expedite the approval process for manufacturers already certified by recognized authorities.

To import pharmaceutical products into Yemen, companies must provide several key documents:

• Certificate of Pharmaceutical Products (COPP): This certificate, legalized by the Yemeni embassy, verifies that the product is legally manufactured and approved in the country of origin.

• Certificate of Analysis (CoA): This document provides detailed information about the product's composition and quality.

• GMP Certificate: This certificate confirms that the manufacturing facility adheres to recognized GMP standards.

Additionally, import licenses and compliance with customs procedures are required for pharmaceutical imports into Yemen.

EXPORT_TRENDS

India's pharmaceutical exports to Yemen are predominantly in the category of "Other medicaments of mixed or unmixed products." In 2022, India exported $37.24 million worth of these products to Yemen, making it the largest exporter in this category. This dominance aligns with Yemen's healthcare needs, which include a diverse range of medications to address various health conditions.

The global pharmaceutical industry is witnessing patent expirations, leading to increased demand for generic medicines. India, being a major producer of generics, is well-positioned to meet this demand in Yemen. Additionally, the rising prevalence of chronic diseases in Yemen presents opportunities for Indian exporters to supply specialized medications and biosimilars.

Yemen's disease burden, including high rates of infectious diseases and chronic conditions, drives the demand for pharmaceutical imports. The aging population and limited local manufacturing capacity further contribute to the reliance on imported medicines. Healthcare spending trends indicate a growing allocation of resources towards pharmaceuticals, enhancing the market potential for Indian exporters.

EXPORT_POLICY

Yemen's tariff structure for pharmaceutical imports includes Most Favored Nation (MFN) tariff rates and preferential rates for certain countries. Duty exemptions may apply to specific pharmaceutical formulations, particularly those addressing critical health needs. However, detailed and up-to-date information on these rates is not readily available and may require direct consultation with Yemeni customs authorities.

Yemen is a member of the Arab Free Trade Area (AFTA), which aims to reduce trade barriers among member countries. While there is no specific Free Trade Agreement (FTA) between India and Yemen, the AFTA framework may facilitate trade between the two nations. Current or upcoming negotiations could further enhance bilateral trade relations.

Yemen's intellectual property (IP) laws, including patent provisions and data exclusivity, are evolving. Compulsory licensing may be granted in cases of public health emergencies, potentially affecting the entry of Indian generics into the Yemeni market. Indian exporters should monitor these developments to navigate the IP landscape effectively.

EXPORT_LOGISTICS

Major sea routes from Indian ports to Yemen include the Arabian Sea and the Gulf of Aden. Transit times vary depending on the specific ports of departure and arrival. Air routes are also utilized, with transit times depending on the specific airports involved. Geopolitical factors, such as the security situation in the Red Sea, can impact shipping routes and schedules.

In India, key export ports include Nhava Sheva Sea (INNSA1), Mundra Sea (INMUN1), and Sahar Air Cargo (INBOM4). In Yemen, major import ports are Hodeidah and Aden. These ports handle a significant volume of pharmaceutical imports, facilitating trade between the two countries.

Temperature-controlled logistics are essential for maintaining the efficacy of pharmaceutical products during transit. Good Distribution Practice (GDP) compliance ensures that products are stored and transported under appropriate conditions. Packaging standards must adhere to international guidelines to prevent contamination and ensure product integrity.

EXPORT_OPPORTUNITY

Yemen's pharmaceutical market is substantial, with imports valued at $127.85 million in 2019. The market is characterized by a high dependency on imports, with generics comprising a significant portion of the market share. This presents a growing opportunity for Indian exporters to meet the increasing demand for affordable and quality medicines.

Yemen's government healthcare programs focus on providing essential medical services to the population. However, challenges such as limited infrastructure and resources affect the efficiency of drug procurement systems. The reliance on international aid and imports underscores the need for reliable pharmaceutical suppliers like India.

Indian exporters have opportunities to supply a wide range of pharmaceutical products to Yemen, particularly in therapeutic areas such as infectious diseases, chronic conditions, and maternal and child health. The growth outlook for Indian pharma in Yemen is positive, driven by the country's healthcare needs and the established trade relationship.

EXPORT_COMPETITIVE

Other countries supplying pharmaceuticals to Yemen include China, the European Union, and regional neighbors like Saudi Arabia and the United Arab Emirates. In 2022, China exported $526.86K worth of hygienic or pharmaceutical articles of vulcanized rubber to Yemen. While these competitors have a presence in the Yemeni market, India's established trade relationship and product diversity provide a competitive edge.

India's advantages in the Yemeni pharmaceutical market include cost-effective production, adherence to WHO-GMP standards, and a broad portfolio of products. These factors enable Indian exporters to offer high-quality medicines at competitive prices, meeting the diverse needs of the Yemeni population.

Key challenges include potential regulatory tightening in Yemen, competition from other suppliers, and perceptions of quality. The geopolitical situation in the region can also impact trade routes and logistics. Indian exporters should proactively address these challenges to maintain and